[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ct":220},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,65,89,125,146,169,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100619980","a-multicenter-prospective-study-on-the-performance-of-spectral-ct-for-evaluating-treatment-response-after-tace-in-hepatocellular-carcinoma-100619980",false,"NCT07351669","A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma","The Performance of Spectral CT in Evaluating Treatment Response After Transarterial Chemoembolization for Hepatocellular Carcinoma: The SpecTRAIL Study","Inclusion Criteria:\n\n1. age 18-75 years;\n2. diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria;\n3. Barcelona Clinic Liver Cancer (BCLC) stage A or B;\n4. prior treatment with TACE;\n5. undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE;\n6. undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort);\n7. informed consent.\n\nExclusion Criteria:\n\n1. contraindications to contrast-enhanced CT or MRI;\n2. presence of extrahepatic malignancy;\n3. poor image quality or incomplete clinical data;\n4. lack of regular CT or MRI follow-up in non-surgical cohort;\n5. withdrawal from the study.","ALL","18 Years","75 Years",{"count":20,"type":21},121,"ESTIMATED","1 Year","OBSERVATIONAL","By comparing the diagnostic accuracy of spectral CT and conventional CT in evaluating treatment response efficacy after TACE, this study aims to investigate the diagnostic performance of spectral CT in assessing treatment response following TACE for hepatocellular carcinoma.",[26,27,28],"HCC - Hepatocellular Carcinoma","TACE(Transcatheter Arterial Chemoembolization)","CT","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-10","ACTUAL",{"date":35,"type":33},"2026-01-20",{"date":37,"type":21},"2028-06-30",{"name":39,"class":40},"Zhongda Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100635933","imaging-based-prediction-of-eligibility-for-chemoimmunotherapy-in-resectable-nsclc-iprecise-100635933","NCT07559123","Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE","iPRECISE","Inclusion Criteria:\n\n* Age: 18 years or older.\n* Diagnosis: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).\n* Staging: Resectable NSCLC of stage IIIA or lower.\n* Treatment Plan: Planned to receive neoadjuvant chemoimmunotherapy before surgery according to standard clinical practice.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Informed Consent: Able and willing to provide written informed consent after receiving a detailed explanation of the study.\n\nExclusion Criteria:\n\n* No Measurable Lesion: Participants must have at least one measurable lesion (\\>= 10 mm on spiral\u002Fmultidetector computed tomography).\n* Prior Malignancy: History of another malignancy within 5 years before enrollment (excluding adequately treated basal cell skin carcinoma or cervical carcinoma in situ).\n* Neurological\u002FPsychiatric Conditions: History of clinically significant uncontrolled seizures, CNS disease, or psychiatric disorders that may interfere with study participation or consent.\n* Contrast Allergy: History of severe allergic reaction to iodinated CT contrast media.\n* Renal Impairment: Acute renal failure or moderate to severe renal impairment (CrCl \\\u003C 45 mL\u002Fmin\u002F1.73 m² or serum creatinine \\> 1.5x upper limit of normal).\n* Recent Surgery: Major surgery within 4 weeks of enrollment or incomplete recovery from major surgery.\n* Pregnancy\u002FNursing: Currently pregnant or breastfeeding; women of childbearing potential without a negative baseline pregnancy test.\n* Contraception: Men or women of childbearing potential unwilling to use appropriate contraception during the study.",{"count":50,"type":21},150,"3 Years","This study is for adults with resectable non-small cell lung cancer who are scheduled to receive neoadjuvant chemoimmunotherapy before surgery.\n\nNeoadjuvant chemoimmunotherapy can help shrink lung cancer before surgery and may improve treatment outcomes. However, not all patients benefit from this treatment in the same way, and it can sometimes cause side effects, such as immune-related pneumonitis. At present, it is still difficult to predict before or during treatment which patients will have a strong response.\n\nThe purpose of this study is to find imaging features on chest computed tomography scans that may help predict how well a patient's cancer responds to neoadjuvant chemoimmunotherapy. The study will compare computed tomography findings before treatment and before surgery with pathologic findings from surgery, including pathologic complete response and major pathologic response. The study will also evaluate whether computed tomography-based imaging features are associated with treatment-related side effects and long-term outcomes such as disease progression and survival.\n\nThis is an observational study. The investigators will not assign participants to a specific cancer treatment. Participants will receive neoadjuvant chemoimmunotherapy and surgery according to standard clinical practice. Chest computed tomography scans will be obtained before treatment and before surgery as part of the study protocol. These computed tomography images will also be reconstructed using a high-resolution deep learning-based computed tomography reconstruction technique to explore whether this approach can improve the development of imaging biomarkers.\n\nThe results of this study may help develop a noninvasive imaging-based model to identify patients who are more likely to benefit from neoadjuvant chemoimmunotherapy and to better guide treatment planning for resectable non-small cell lung cancer.",[54,55,28],"NSCLC","Neoadjuvant Chemoimmunotherapy","2026-05-05",{"date":58,"type":33},"2026-05-08",{"date":60,"type":33},"2026-02-01",{"date":62,"type":21},"2028-12",{"name":64,"class":40},"Samsung Medical Center",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100617564","cardiac-ct-evaluation-of-eat-in-af-vs-non-af-subjects-100617564","NCT07320261","Cardiac CT Evaluation of EAT in AF vs. Non-AF Subjects","Cardiac Computed Tomography Evaluation of Epicardial Adipose Tissue Differences Between Patients With Atrial Fibrillation and Non-Atrial Fibrillation Individuals","CCT-EAT-AF-NA","Inclusion Criteria:\n\n* Patients who undergo coronary CTA or left atrial CTA examination at The Second Affiliated Hospital of Zhejiang University School of Medicine;\n* Aged 18 years or older\n* Cardiac rhythm status is confirmed as sinus rhythm, paroxysmal atrial fibrillation, or persistent atrial fibrillation;\n* Willing to provide clinical baseline data and allow access to CTA examination results;\n* Able to understand and cooperate with the data collection process of the study.\n\nExclusion Criteria:\n\n* Patients with incomplete clinical baseline data or unreadable CTA images;\n* Aged less than 18 years\n* Patients who refuse to participate in the study or cannot cooperate with data collection;\n* Other situations judged by the researchers to be unsuitable for inclusion in the study.",true,{"count":75,"type":21},600,"The goal of this cross-sectional study is to explore the relationship between atrial structural characteristics (such as epicardial adipose tissue infiltration and atrial size) and atrial fibrillation (AF), as well as the differences in these characteristics among different AF subtypes. It will also clarify the independent association between pericardial fat distribution and AF (and its subtypes) after excluding confounding factors.\n\nThe main questions it aims to answer are:\n\n* What are the differences in epicardial adipose tissue volume and atrial size among patients with sinus rhythm, paroxysmal AF, and persistent AF?\n* Is pericardial fat distribution independently associated with AF and its subtypes after adjusting for confounding factors such as age, hypertension, and left atrial enlargement?\n\nResearchers will enroll patients who undergo coronary CTA or left atrial CTA at The Second Affiliated Hospital of Zhejiang University School of Medicine, and match and divide them into three groups (sinus rhythm group, paroxysmal AF group, and persistent AF group) based on BMI and other factors. They will compare the differences in pericardial fat distribution and baseline characteristics among the three groups and analyze the independent association between pericardial fat and AF.\n\nParticipants will:\n\n* Provide relevant clinical baseline data and CTA examination results\n* Complete the collection of demographic information, medical history, and laboratory test data\n\nThe study duration is 6 months, starting from the date of ethical approval, with an expected end date of June 2026. A total of 600-900 participants (200-300 per group) will be enrolled to ensure the reliability and clinical applicability of the research conclusions.",[78,28],"Atrial Fibrillation (AF)","NOT_YET_RECRUITING","2025-12-22",{"date":82,"type":33},"2026-01-06",{"date":84,"type":21},"2026-01-01",{"date":86,"type":21},"2026-08",{"name":88,"class":40},"xiaoya wang",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":97,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100612087","this-is-a-multicentre-international-study-evaluating-ct-based-igabt-with--without-either-trus-during-btpre-bt-mr-as-per-ibs-gecestro-abs-recommendations-for-target-contouring-as-an-alternative-to-mrigabt-for-cervical-cancer-from-implementation-perspectives-under-embrace-iiitriplet-impact-study-100612087","NCT07249021","This is a Multicentre International Study Evaluating CT-based IGABT With \u002F Without Either TRUS During BT\u002FPre BT MR as Per IBS-GECESTRO-ABS Recommendations for Target contouring-as an Alternative to MRIGABT for Cervical Cancer From Implementation Perspectives Under EMBRACE-III:TRIPLET IMPACT Study.","Integration of Multi-modality Imaging Protocols With emphAsis on CT in Image Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-IMPACT STUDY","IMPACT","Inclusion Criteria:\n\n1. Cancer of the uterine cervix considered suitable for curative treatment with definitive chemo radiotherapy including brachytherapy.\n2. Biopsy showing invasive squamous-cell carcinoma or adenocarcinoma or adeno - squamous cell carcinoma of the uterine cervix.\n3. FIGO (2018) stage IB2 to IVA\n4. Willingness to participate by signing informed consent form.\n\nExclusion Criteria:\n\n* Other previous or current primary malignancies except carcinoma in situ of the cervix.\n\n  * Metastatic Inguinal Nodes not amenable to radical radiation therapy\n  * Metastatic disease in para-aortic region beyond renal vessels\n  * Not eligible for concurrent cisplatin chemotherapy (creatinine clearance \\\u003C 50mg\u002Fml\u002Fmin)\n  * Previous pelvic or abdominal radiotherapy.\n  * Previous total or partial hysterectomy.\n  * Patients receiving BT alone.\n  * Patients receiving EBRT alone.\n  * Patients receiving any form of neoadjuvant anti-neoplastic therapy prior to definitive treatment or adjuvant therapy\n  * Active infection or severe medical condition which precludes radical chemoradiotherapy.\n  * Pregnant or lactating or childbearing potential without adequate contraception.","FEMALE",{"count":99,"type":21},1200,"Title: Integration of Multi-modality Imaging Protocols with Emphasis on CT in Image-Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-TRIPLET : IMPACT Study Locally advanced cervical cancer (LACC) remains a major health challenge, particularly in low- and middle-income countries (LMICs), which account for the majority of global cases. The standard curative treatment involves a combination of external beam radiotherapy (EBRT) with concurrent chemotherapy, followed by brachytherapy (BT). Brachytherapy plays a crucial role in achieving high local control by delivering radiation directly to the tumour through internally placed radioactive sources.\n\nHistorically, BT dose prescription was based on two-dimensional (2D) X-ray images and defined anatomical \"points,\" achieving 5-year local control rates of 60-70%. Over the last decade, magnetic resonance imaging (MRI)-based image-guided adaptive brachytherapy (MR-IGABT) has transformed practice by enabling three-dimensional (3D) target-based dose prescription and adaptation to tumour regression. The landmark EMBRACE I study, involving over 1300 patients, demonstrated over 90% 5-year local control rates with MR-IGABT, establishing it as the international gold standard endorsed by NCG, ICRU, NCCN, and ESGO-ESTRO guidelines.\n\nHowever, MRI-based planning for IGABT remains logistically and financially challenging for many centres, especially in LMICs. CT and transrectal ultrasound (TRUS) have emerged as feasible alternatives, offering broader accessibility. Despite encouraging outcomes from smaller institutional studies, the lack of standardized and validated target delineation concepts for CT-IGABT has led to significant variability in clinical implementation. Recognizing this, the Indian Brachytherapy Society (IBS), American Brachytherapy Society (ABS), and GEC-ESTRO jointly published consensus recommendations in 2020 to standardize CT-IGABT practices across diverse clinical environments.\n\nAt Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, our prior work (RetroLACER Study) demonstrated that CT-based IGABT can achieve outcomes comparable to MR-IGABT, highlighting its feasibility and potential for wider adoption. Building on this foundation, the EMBRACE III-IMPACT Study seeks to evaluate whether CT-IGABT can be systematically and uniformly implemented in a multi-centre setting and to benchmark clinical outcomes against the standards set by MR-IGABT.\n\nStudy Design:\n\nThis is a multicentre, prospective, observational study planned to include approximately 1200 participants with locally advanced cervical cancer. All participants will receive standard-of-care treatment, including EBRT, concurrent weekly cisplatin chemotherapy, and brachytherapy with image-guided planning.\n\nObjectives:\n\nTo assess the feasibility of implementing standardized CT-IGABT protocols across diverse clinical environments.\n\nTo evaluate local control, disease-free survival, and treatment-related toxicity outcomes for CT-IGABT.\n\nTo compare and benchmark CT-IGABT outcomes with established MR-IGABT benchmarks from prior international studies.\n\nParticipant Involvement:\n\nParticipants will undergo standard diagnostic imaging, EBRT with weekly cisplatin, and brachytherapy using CT-based planning. Imaging and treatment data will be collected, anonymized, and submitted to a central database for review. Regular follow-up visits will monitor tumour control and treatment-related side effects.\n\nBenefits:\n\nParticipants receive internationally standardized, quality-assured treatment protocols. Centres gain access to expert review and QA support from international collaborators, potentially improving treatment quality and outcomes.\n\nThe study supports global efforts to establish CT-IGABT as a cost-effective, accessible alternative to MRI-based IGABT, expanding equitable cancer care access.\n\nRisks:\n\nThe study is observational and involves standard treatment; therefore, risks and costs are comparable to routine cervical cancer care.\n\nConfidentiality and Ethics:\n\nAll data will be anonymized and handled in compliance with ethical and regulatory standards. Participant confidentiality will be strictly maintained. Written informed consent will be obtained before study participation.\n\nSignificance:\n\nBy validating standardised CT-based protocols and establishing outcome benchmarks, the study aims to facilitate widespread adoption of IGABT in resource-limited settings, ultimately improving treatment accessibility and survival outcomes.",[102,103,28,104],"Locally Advanced Cervical Cancer","Brachytherapy","Transrectal Ultrasound",[106,107,108,109,110,111,112,113,114,115],"Cervical cancer","CT-guided brachytherapy","Image-Guided Adaptive Brachytherapy (IGABT)","Locally advanced cervical cancer","Implementation study","Resource-limited settings","Low- and middle-income countries (LMICs)","EMBRACE III","Trans-rectal ultrasound during BT","Pre BT MR Imaging","2025-11-21",{"date":118,"type":33},"2025-11-25",{"date":120,"type":21},"2025-11",{"date":122,"type":21},"2031-11",{"name":124,"class":40},"Homi Bhabha Cancer Hospital & Research Centre",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100607054","ct-volume-measurement-of-hepatocellular-carcinoma-100607054","NCT07183566","CT Volume Measurement of Hepatocellular Carcinoma","Ct Volume Measurement of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) or Microwave Ablation (MWA)","Inclusion Criteria:\n\n* Adult patients (≥18 years) with a confirmed diagnosis of HCC based on AASLD or EASL criteria.\n* Patients deemed unresectable by the multidisciplinary tumor board.\n* Patients scheduled for TACE as the primary locoregional therapy.\n* Preserved liver function (Child-Pugh class A or B).\n* Adequate renal function to permit contrast-enhanced CT.\n\nExclusion Criteria:\n\n* Patients with extrahepatic metastases or portal vein thrombosis.\n* Patients with contraindications to iodinated contrast or TACE.\n* Patients with severe comorbid illness that precludes participation.\n* Patients refuse to provide informed consent.",{"count":133,"type":21},66,"The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)",[136,28],"Hepatocellular Carcinoma (HCC)","2025-09-17",{"date":139,"type":33},"2025-09-19",{"date":141,"type":21},"2025-10-01",{"date":143,"type":21},"2027-11-01",{"name":145,"class":40},"Assiut University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":41},"100595770","coronary-evaluation-and-guided-lesion-exploration-using-photon-counting-ct-and-intracoronary-imaging-techniques-100595770","NCT07036770","Coronary Evaluation And Guided Lesion Exploration Using Photon-counting CT and Intracoronary Imaging Techniques","C-EAGLE","Inclusion criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Patients presenting with suspected acute coronary syndrome (UA or NSTEMI) or chronic coronary syndrome (stable angina or silent ischemia).\n\nExclusion criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n1. Patients presenting with STEMI.\n2. Haemodynamically unstable patients.\n3. Unstable ventricular arrhythmias.\n4. Killip class III-IV heart failure.\n5. Creatinine clearance \\\u003C30 ml\u002Fmin\u002F1.73 m2 (as calculated by CKD-EPI formula 2009 for estimated GFR) and not on dialysis. Note: patients dependent on long-term dialysis are eligible for enrolment irrespective of their creatinine clearance levels.\n6. Severe coronary vessel tortuosity.\n7. Subject has known hypersensitivity to radiocontrast dye or that cannot be adequately pre-medicated.\n8. Female who is pregnant or breast-feeding.",{"count":154,"type":21},100,"This study evaluates the diagnostic accuracy and limitations of photon-counting computed tomography (PCCT) in characterizing coronary plaque, with comparisons to optical coherence tomography (OCT) and intravascular ultrasound (IVUS). The objective is to assess whether cardiac ultra-high resolution (UHR) PCCT -with its improved spatial resolution and superior soft tissue contrast relative to conventional CT- can serve as a reliable, non-invasive alternative for coronary plaque assessment and support clinical decision-making. A total of 100 patients with either acute or chronic coronary syndrome will be enrolled, including 40 individuals with suspected in-stent restenosis and 10 patients one year post-percutaneous coronary intervention (PCI) for chronic total occlusion (CTO). All participants will undergo invasive coronary angiography based on current European Society of Cardiology guidelines. Cardiac PCCT imaging will be conducted shortly before the angiographic procedure, accompanied by invasive OCT evaluation. Additionally, a subgroup of 10 patients will undergo both OCT and IVUS, allowing for direct comparison across imaging modalities. OCT, regarded as the gold standard for plaque characterization, offers near-histological resolution for identifying plaque features, while IVUS is particularly effective in evaluating plaque burden and volume.",[157,158,28],"Coronary Artery Disease","OCT Angiography",[160],"PCCT","2025-06-16",{"date":163,"type":33},"2025-06-25",{"date":161,"type":21},{"date":166,"type":21},"2027-05-31",{"name":168,"class":40},"Universitaire Ziekenhuizen KU Leuven",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":41},"100582928","energy-ct-in-imaging-and-diagnosis-of-gastric-cancer-100582928","NCT06869694","Energy CT in Imaging and Diagnosis of Gastric Cancer","Diagnostic and Predictive Performance of Dual-\u002F Muti- Energy CT and MRI in the Treatment Response and Survival Prognosis of Gastric Cancer","CTIDGC","Inclusion Criteria:\n\n1. Pathological biopsy confirmed gastric cancer;\n2. Surgery: patients undergoing radical gastrectomy. Patients undergoing exploratory abdominal surgery or palliative tumor resection were still included in the study when peritoneal metastasis or adjacent organ invasion was identified intraoperatively and radical surgical resection was not possible.\n\nExclusion Criteria:\n\n1. Refusal or inability to sign informed consent;\n2. CT or MRI images are poor or the focus is small and CT images are not clear;\n3. Patients with other tumors complicated with patients with important organ dysfunction.",{"count":178,"type":21},300,"Accurate preoperative prediction of risk stratification, treatment response, and survival prognosis in gastric cancer is important for improving clinical treatment decisions, prolonging patient survival, and improving patient quality of life. The purpose of this study is to investigate the performance of the multi-parametric magnetic resonance imaging (mpMRI) and Dual-\u002FMuti-energy CT and photon-counting Detector CT(PCD-CT) in the diagnosis and management of gastric cancer.",[181,28],"Gastric Cancer",[28,183],"Gastric cancer","2025-03-06",{"date":186,"type":33},"2025-03-11",{"date":188,"type":33},"2024-09-01",{"date":190,"type":21},"2028-09-01",{"name":192,"class":40},"The First Affiliated Hospital of Zhengzhou University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100493518","early-neuroprognostication-after-ohca-100493518","NCT05706194","Early Neuroprognostication After OHCA","Early Neurological Prognostication of Outcome After Out-of-hospital Cardiac arrest-a STEPCARE Prospective Substudy","Inclusion Criteria:\n\nAdult cardiac arrest patients with an out-of-hospital cardiac arrest of non-traumatic cause treated at hospitals recruiting patients to the STEPCARE neuroprognostication substudy. Other inclusion criteria include:\n\n* a minimum of 20 minutes without chest compressions\n* Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of \\\u003C4) or being intubated and sedated because of agitation after sustained ROSC\n* Eligible for intensive care without restrictions or limitations\n* Inclusion within 4 hours of ROSC\n\nExclusion Criteria:\n\n* On ECMO prior to randomisation\n* Pregnancy\n* Suspected or confirmed intracranial hemorrhage\n* Previously randomised in the STEPCARE trial\n* Patients with limitations in level-of-care due to for example generalized malignancy","100 Years",{"count":202,"type":21},1000,"This is a prospective observational substudy of the STEPCARE trial ClinicalTrials.gov Identifier: NCT05564754) with the aim to examine whether prognostication of neurological outcome after cardiac arrest can be performed earlier than the 72 h time-point recommended by guidelines today.",[205,206,207,28,208,209],"Cardiac Arrest","Neurological Outcome","EEG","Brain Injuries","Biomarkers","2024-03-20",{"date":212,"type":33},"2024-03-21",{"date":214,"type":33},"2023-10-01",{"date":216,"type":21},"2029-07-31",{"name":218,"class":40},"Lund University",4,""]